Yike Gao

ORCID: 0000-0002-4196-1700
Publications
Citations
Views
---
Saved
---
About
Contact & Profiles
Research Areas
  • Ovarian cancer diagnosis and treatment
  • Parathyroid Disorders and Treatments
  • Genetic Syndromes and Imprinting
  • Immune Cell Function and Interaction
  • Cancer-related molecular mechanisms research
  • Neurological Disease Mechanisms and Treatments
  • Adipokines, Inflammation, and Metabolic Diseases
  • Adipose Tissue and Metabolism
  • Lymphoma Diagnosis and Treatment
  • Internet Traffic Analysis and Secure E-voting
  • Barrier Structure and Function Studies
  • Network Traffic and Congestion Control
  • Cancer, Hypoxia, and Metabolism
  • Single-cell and spatial transcriptomics
  • Traffic Prediction and Management Techniques
  • Caveolin-1 and cellular processes
  • Medical Imaging and Pathology Studies
  • DNA Repair Mechanisms
  • Cancer Immunotherapy and Biomarkers
  • Medical Research and Treatments
  • Renal cell carcinoma treatment
  • Cardiovascular Disease and Adiposity
  • Pancreatic and Hepatic Oncology Research
  • Microtubule and mitosis dynamics

Peking Union Medical College Hospital
2022-2024

Chinese Academy of Medical Sciences & Peking Union Medical College
2022-2024

Capital Medical University
2024

Imperial College London
2019

Abstract Aim As the second most prevalent subtype of epithelial ovarian cancers, clear cell carcinoma (OCCC) is known for its chemoresistance to conventional platinum‐based therapy. In this work, we examined tryptophan (Trp) metabolism enzymes' differential expression in patients with OCCC assess potential personalised treatment. Methods A total 127 tissues were used construct tissue microarrays, and immunohistochemistry (IHC) staining Trp enzymes IDO1, IDO2, TDO2 IL4I1 was performed. The...

10.1002/cam4.6778 article EN cc-by Cancer Medicine 2023-12-01

Abstract Background Ovarian clear cell carcinoma (OCCC), well known for its chemoresistance to platinum-based chemotherapy, exhibited a good response in clinical trials of anti–PD-1/PD-L1 inhibitors. By assessing PD-L1 expression, we sought determine the potential therapeutic benefit PD-1/PD-L1 inhibitors OCCC. Methods and results The retrospective study included 152 individuals with OCCC between 2019 2022 at Peking Union Medical College Hospital. Paired tumors primary versus recurrent...

10.1186/s13000-024-01510-4 article EN cc-by Diagnostic Pathology 2024-06-15

Abstract Background Metabolites of tryptophan (Trp) metabolism in the tumor microenvironment play crucial immunosuppressive roles various cancers. However, role Trp diffuse large B‐cell lymphoma (DLBCL) or natural killer/T‐cell (NK/TCL) remains unelucidated. Methods We investigated potential a cohort 43 patients with DLBCL and 23 NK/TCL. constructed tissue microarrays performed situ staining Trp‐catabolizing enzymes PD‐L1 using immunohistochemistry (IHC). Results observed 14.0% positive IDO1...

10.1002/cam4.5903 article EN cc-by Cancer Medicine 2023-05-06

Abstract The two most prevalent subtypes of epithelial ovarian carcinoma (EOC) are clear cell (OCCC) and high-grade serous (HGSC). Patients with OCCC have a poor prognosis than those HGSC due to chemoresistance, implying the need for novel treatment target. In this study, we applied single-cell RNA sequencing (scRNA-seq) together bulk RNA-seq data from GEO (Gene Expression Omnibus) database (the GSE189553 dataset) characterize compare tumor heterogeneity cell-level evolution between samples....

10.1186/s13578-023-01087-3 article EN cc-by Cell & Bioscience 2023-07-31
Coming Soon ...